How Can We Engineer CAR T Cells to Overcome Resistance?

Chimeric antigen receptor (CAR) T cell therapy has achieved unrivalled success in the treatment of B cell and plasma cell malignancies, with five CAR T cell products now approved by the US Food and Drug Administration (FDA). However, CAR T cell therapies for solid tumours have not been nearly as suc...

Descripción completa

Detalles Bibliográficos
Autores principales: Glover, Maya, Avraamides, Stephanie, Maher, John
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8141613/
https://www.ncbi.nlm.nih.gov/pubmed/34040345
http://dx.doi.org/10.2147/BTT.S252568

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8141613/
https://www.ncbi.nlm.nih.gov/pubmed/34040345
http://dx.doi.org/10.2147/BTT.S252568

Ejemplares similares